Avanos Medical, Inc. (AVNS)
Total Valuation
Avanos Medical has a market cap or net worth of $1.30 billion. The enterprise value is $1.46 billion.
| Market Cap | 1.30B |
| Enterprise Value | 1.46B |
Important Dates
The next earnings date is Wednesday, May 3, 2023, before market open.
| Estimated Earnings Date | May 3, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Avanos Medical has 46.60 million shares outstanding. The number of shares has decreased by -3.51% in one year.
| Shares Outstanding | 46.60M |
| Shares Change (YoY) | -3.51% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 3.01% |
| Owned by Institutions (%) | 95.13% |
| Float | 43.56M |
Valuation Ratios
The trailing PE ratio is 26.29.
| PE Ratio | 26.29 |
| Forward PE | n/a |
| PS Ratio | 1.60 |
| Forward PS | 1.57 |
| PB Ratio | 1.02 |
| P/FCF Ratio | 18.32 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.91, with an EV/FCF ratio of 20.44.
| EV / Earnings | 28.98 |
| EV / Sales | 1.79 |
| EV / EBITDA | 11.91 |
| EV / EBIT | 19.46 |
| EV / FCF | 20.44 |
Financial Position
The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.69 |
| Quick Ratio | 1.59 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 2.28 |
| Debt / FCF | 3.91 |
Financial Efficiency
Return on equity (ROE) is 4.00% and return on invested capital (ROIC) is 10.60%.
| Return on Equity (ROE) | 4.00% |
| Return on Assets (ROA) | 2.90% |
| Return on Capital (ROIC) | 10.60% |
| Revenue Per Employee | $180,022 |
| Profits Per Employee | $11,087 |
| Employee Count | 4,555 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 2.12 |
Taxes
In the past 12 months, Avanos Medical has paid $14.70 million in taxes.
| Income Tax | 14.70M |
| Effective Tax Rate | 22.55% |
Stock Price Statistics
The stock price has decreased by -12.20% in the last 52 weeks. The beta is 0.93, so Avanos Medical's price volatility has been similar to the market average.
| Beta (1Y) | 0.93 |
| 52-Week Price Change | -12.20% |
| 50-Day Moving Average | 29.27 |
| 200-Day Moving Average | 26.44 |
| Average Volume (30 Days) | 250,664 |
Short Selling Information
The latest short interest is 1.06 million, so 2.28% of the outstanding shares have been sold short.
| Short Interest | 1.06M |
| Short Previous Month | 910,727 |
| Short % of Shares Out | 2.28% |
| Short % of Float | 2.44% |
| Short Ratio (days to cover) | 5.02 |
Income Statement
In the last 12 months, Avanos Medical had revenue of $820.00 million and earned $50.50 million in profits. Earnings per share was $1.07.
| Revenue | 820.00M |
| Gross Profit | 450.00M |
| Operating Income | 77.50M |
| Pretax Income | 65.20M |
| Net Income | 50.50M |
| EBITDA | 122.90M |
| EBIT | 75.20M |
| Earnings Per Share (EPS) | $1.07 |
Balance Sheet
The company has $127.70 million in cash and $280.00 million in debt, giving a net cash position of -$152.30 million or -$3.27 per share.
| Cash & Cash Equivalents | 127.70M |
| Total Debt | 280.00M |
| Net Cash | -152.30M |
| Net Cash Per Share | -$3.27 |
| Equity / Book Value | 1.29B |
| Book Value Per Share | 27.71 |
| Working Capital | 314.00M |
Cash Flow
In the last 12 months, operating cash flow was $90.90 million and capital expenditures -$19.30 million, giving a free cash flow of $71.60 million.
| Operating Cash Flow | 90.90M |
| Capital Expenditures | -19.30M |
| Free Cash Flow | 71.60M |
| FCF Per Share | $1.54 |
Margins
Gross margin is 54.88%, with operating and profit margins of 9.45% and 6.16%.
| Gross Margin | 54.88% |
| Operating Margin | 9.45% |
| Pretax Margin | 7.95% |
| Profit Margin | 6.16% |
| EBITDA Margin | 14.99% |
| EBIT Margin | 9.17% |
| FCF Margin | 8.73% |
Dividends & Yields
Avanos Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 3.85% |
| FCF Yield | 5.46% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.51% |
| Shareholder Yield | 3.51% |
Analyst Forecast
The average price target for Avanos Medical is $29.58, which is 5.68% higher than the current price. The consensus rating is "Sell".
| Price Target | $29.58 |
| Price Target Difference | 5.68% |
| Analyst Consensus | Sell |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |